The results of animal and cellular experiments demonstrated that p65/S536D inhibits HCC progression and metastasis by blocking NF-κB p65 entry into the nucleus, inhibiting BCL2, SNAIL, and MMP9, and reversing the epithelial–mesenchymal transition (EMT). Here, BCL2 is linked to hepatocellular carcinoma.